Product Information
IMATINIB MESYLATE 100 MG TAB is a generic product labeled by Sun Pharmaceutical Industries Inc., priced at $0.6114 per EA under NDC 47335047281. Its NADAC has been published 470 times since Sep 21, 2016.
FDA first approved this application on Dec 3, 2015.
Strength
100 mg/1
Manufacturer
Sun Pharmaceutical Industries Inc.NDC
47335047281
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
IMATINIB MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA078340FDA Approved
12/3/2015
On Market Since
2/1/2016
Pharmacological Classes
Price Statistics
The NADAC for IMATINIB MESYLATE 100 MG TAB has been published 470 times since Sep 21, 2016, and over the history we have for it it has declined 99.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6114 per EA |
|---|---|
| All-time high | $74.5901 (Nov 16, 2016) |
| All-time low | $0.3890 (May 22, 2024) |
| 52-week high | $0.9248 |
| 52-week low | $0.6114 |
| Median price | $2.0686 |
| Average price | $13.1824 |
| Largest weekly change | -82.3% (Oct 17, 2018) |
| Weeks tracked | 470 |
| Tracking since | Sep 21, 2016 |
1W
N/A
1M
N/A
3M
-7.8%
6M
-26.1%
1Y
-33.9%
3Y
+0.4%
5Y
-80.5%
All
-99.2%
Last surveyed Aug 19, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 20% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sun Pharmaceutical Industries Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
imatinib mesylate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IMATINIB MESYLATE 100 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for IMATINIB MESYLATE 100 MG TAB, manufactured by Sun Pharmaceutical Industries Inc., is $0.6114 per EA (NDC 47335047281), effective Aug 19, 2026.
How has the price of IMATINIB MESYLATE 100 MG TAB changed over time?
Over the history we have for it, the NADAC for IMATINIB MESYLATE 100 MG TAB has declined 99.2%. It has been tracked across 470 weekly CMS publications since Sep 21, 2016.
What are the highest and lowest recorded NADAC prices for IMATINIB MESYLATE 100 MG TAB?
Since Sep 21, 2016, the NADAC for IMATINIB MESYLATE 100 MG TAB has ranged from a low of $0.3890 (May 22, 2024) to a high of $74.5901 (Nov 16, 2016), with a median of $2.0686 per EA.
Are there cheaper alternatives to IMATINIB MESYLATE 100 MG TAB?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IMATINIB MESYLATE 100 MG TAB, is $0.4912 per EA — about 20% below IMATINIB MESYLATE 100 MG TAB.
Who manufactures IMATINIB MESYLATE 100 MG TAB?
IMATINIB MESYLATE 100 MG TAB (NDC 47335047281) is labeled by Sun Pharmaceutical Industries Inc., and CMS classifies it as a generic product.